Subscriber Only
Markets
Deals
Sanofi to Explore Counterbid for Actelion Amid J&J Talks
- French drugmaker said to work with advisers to weigh options
- Actelion said to be valued at over $27 billion in J&J offer

Sanofi Said to Weigh Actelion Bid Challenging J&J
Updated on